RxDoctor Payments Data

Anthony Flood, MD

Family Medicine · Washington, DCNPI 1083879035

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $314 and has fallen 68.4% since, to $99 in 2024.

$1,176in general payments, 2019–2025

Across 65 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$256
  • Mayne Pharma Commercial LLC$187
  • Arcutis Biotherapeutics, Inc.$158
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$132
  • AbbVie$91
  • Sun Pharmaceutical Industries Inc.$77
  • plus $275 from 7 others

What the payments were for

  • Food & beverage$1,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,176 in reported general payments places this provider in the 85th percentile of 166 family medicine providers in District of Columbia.

See all family medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$178,503
Medicare patients
299
Services billed
3,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$72,256
Fluocinonide505$29,992
Metronidazole202$16,944
Clobetasol Propionate191$15,556
ErythromycinErythromycin Base70$10,774
Ammonium Lactate395$10,716
Desonide166$10,181
Doxepin Hcl154$8,962
Betamethasone Valerate240$7,399
Tretinoin66$6,406
Acitretin38$5,685
Erythromycin-Benzoyl PeroxideErythromycin/Benzoyl Peroxide48$3,769
Ketoconazole260$3,683
Betamethasone Dipropionate52$3,477
Fluocinolone Acetonide57$3,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$35$72,25614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 166 family medicine providers in District of Columbia.

Other family medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →